Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
What’s Next For Cambritaxestat?
Industry Insight
Realizing the potential of PI3Kδ inhibitors in peripheral T-cell lymphomas
Industry Insight
iOnctura Expands Roginolisib Trials to the US
Industry Insight
iOnctura Enhances Board to Accelerate Growth and Innovation
Industry Insight
Addressing Drug Resistance in Non-Small Cell Lung Cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Download our corporate deck
Find out more about our mission to give patients more momets that matter
All news
Data & publication
Safety and clinical efficacy of roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase Inhibitor delta (PI3Kδ)
Press coverage
pharmaphorum — Uveal melanoma: a new generation of therapies offers hope for patients
Press coverage
Immuno-Oncology Insights — Navigating the complexities of immunotherapy: unraveling novel targets & pathways
Press coverage
Drug Target Review — Combining autotaxin and TGF-β inhibitors in cancer
Press release
iOnctura to present research on roginolisib and IOA-359 at ASH
Press coverage
Labiotech — Could this be the start of a new era for PI3K drugs?
Press release
iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ
Press release
New research highlights potential of iOnctura strategy combining autotaxin and TGF-β inhibitors in cancer
Data & publication
Autotaxin secretion is a stromal mechanism of adaptive resistance to TGFβ inhibition in pancreatic ductal adenocarcinoma
Press coverage
Drug Discovery World — Meet the researcher: Giusy Di Conza
Data & publication
Non-clinical toxicology evaluation of the novel non-ATP competitive oral PI3 kinase delta inhibitor roginolisib
Press coverage
pharmaphorum — Realising the potential of autotaxin inhibition in cancer
Looking for media
resources?